These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10203053)

  • 41. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.
    Gorelick RJ; Benveniste RE; Lifson JD; Yovandich JL; Morton WR; Kuller L; Flynn BM; Fisher BA; Rossio JL; Piatak M; Bess JW; Henderson LE; Arthur LO
    J Virol; 2000 Dec; 74(24):11935-49. PubMed ID: 11090194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection.
    Hu SL; Polacino P; Stallard V; Klaniecki J; Pennathur S; Travis BM; Misher L; Kornas H; Langlois AJ; Morton WR; Benveniste RE
    Immunol Lett; 1996 Jun; 51(1-2):115-9. PubMed ID: 8811354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
    Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
    J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals.
    Greenier JL; Van Rompay KK; Montefiori D; Earl P; Moss B; Marthas ML
    Virol J; 2005 Feb; 2():11. PubMed ID: 15710048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines.
    Polacino P; Stallard V; Montefiori DC; Brown CR; Richardson BA; Morton WR; Benveniste RE; Hu SL
    J Virol; 1999 Apr; 73(4):3134-46. PubMed ID: 10074165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.
    Fuller DH; Rajakumar PA; Wilson LA; Trichel AM; Fuller JT; Shipley T; Wu MS; Weis K; Rinaldo CR; Haynes JR; Murphey-Corb M
    J Virol; 2002 Apr; 76(7):3309-17. PubMed ID: 11884556
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.
    Schulte R; Suh YS; Sauermann U; Ochieng W; Sopper S; Kim KS; Ahn SS; Park KS; Stolte-Leeb N; Hunsmann G; Sung YC; Stahl-Hennig C
    Virology; 2009 Jan; 383(2):300-9. PubMed ID: 19027133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV.
    Fuller DH; Simpson L; Cole KS; Clements JE; Panicali DL; Montelaro RC; Murphey-Corb M; Haynes JR
    Immunol Cell Biol; 1997 Aug; 75(4):389-96. PubMed ID: 9315483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.
    Santra S; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Lord CI; Pal R; Franchini G; Letvin NL
    J Immunol; 2002 Feb; 168(4):1847-53. PubMed ID: 11823518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.
    Boyer JD; Robinson TM; Maciag PC; Peng X; Johnson RS; Pavlakis G; Lewis MG; Shen A; Siliciano R; Brown CR; Weiner DB; Paterson Y
    Virology; 2005 Mar; 333(1):88-101. PubMed ID: 15708595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge.
    Busch M; Abel K; Li J; Piatak M; Lifson JD; Miller CJ
    Vaccine; 2005 Jul; 23(31):4036-47. PubMed ID: 15963361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
    Hel Z; Tsai WP; Thornton A; Nacsa J; Giuliani L; Tryniszewska E; Poudyal M; Venzon D; Wang X; Altman J; Watkins DI; Lu W; von Gegerfelt A; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
    J Immunol; 2001 Dec; 167(12):7180-91. PubMed ID: 11739541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.
    Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM
    AIDS Res Hum Retroviruses; 2003 Oct; 19(10):891-900. PubMed ID: 14585221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.
    Willer DO; Guan Y; Luscher MA; Li B; Pilon R; Fournier J; Parenteau M; Wainberg MA; Sandstrom P; MacDonald KS
    J Virol; 2010 Mar; 84(5):2304-17. PubMed ID: 20032177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.
    Leno M; Carter L; Venzon DJ; Romano J; Markham PD; Limbach K; Tartaglia J; Paoletti E; Benson J; Franchini G; Robert-Guroff M
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):461-70. PubMed ID: 10195756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration.
    O'Neill E; Martinez I; Villinger F; Rivera M; Gascot S; Colon C; Arana T; Sidhu M; Stout R; Montefiori DC; Martinez M; Ansari AA; Israel ZR; Kraiselburd E
    J Med Primatol; 2002 Aug; 31(4-5):217-27. PubMed ID: 12390544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.